table of contents hologic , inc . notes to consolidated financial statements ( continued ) ( all tabular amounts in thousands except per share data ) which the cytyc stockholders received a premium over the fair market value of their shares on such date and cash of $ 16.50 per share ( or approximately 35% ( 35 % ) of the merger consideration ) . there were no preexisting relationships between the two companies . cytyc , headquartered in marlborough , massachusetts , is a diversified diagnostic and medical device company that designs , develops , manufactures , and markets innovative and clinically effective diagnostics and surgical products . cytyc products cover a range of cancer and women 2019s health applications , including cervical cancer screening , prenatal diagnostics , treatment of excessive menstrual bleeding and radiation treatment of early-stage breast cancer . upon the close of the merger , cytyc shareholders received an aggregate of 132 million shares of hologic common stock and $ 2.1 billion in cash . in connection with the close of the merger , the company entered into a credit agreement relating to a senior secured credit facility ( the 201ccredit agreement 201d ) with goldman sachs credit partners l.p . and certain other lenders , in which the lenders committed to provide , in the aggregate , senior secured financing of up to approximately $ 2.55 billion to pay for the cash portion of the merger consideration , repayment of existing debt of cytyc , expenses relating to the merger and working capital following the completion of the merger . as of the closing of the merger , the company borrowed $ 2.35 billion under this credit agreement . see note 5 for further discussion . the aggregate purchase price of approximately $ 6.16 billion included $ 2.1 million in cash ; 132 million shares of hologic common stock at an estimated fair value of $ 3.67 billion ; 16.5 million of fully vested stock options granted to cytyc employees in exchange for their vested cytyc stock options , with an estimated fair value of approximately $ 241.4 million ; the fair value of cytyc 2019s outstanding convertible notes assumed in the merger of $ 125.0 million ; and approximately $ 24.2 million of direct acquisition costs . there were no potential contingent consideration arrangements payable to the former cytyc shareholders in connection with this transaction . the company measured the fair value of the 132 million shares of the company common stock issued as consideration in connection with the merger under eitf 99-12 . the company determined the measurement date to be may 20 , 2007 , the date the transaction was announced , as the number of shares to be issued according to the exchange ratio was fixed without subsequent revision . the company valued the securities based on the average market price a few days before and after the measurement date . the weighted average stock price was determined to be $ 27.81 . ( i ) purchase price the purchase price is as follows: .

Table: cash portion of consideration $ 2094800 fair value of securities issued 3671500 fair value of vested options exchanged 241400 fair value of cytyc 2019s outstanding convertible notes 125000 direct acquisition costs 24200 total estimated purchase price $ 6156900

source : hologic inc , 10-k , november 24 , 2010 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely . the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law . past financial performance is no guarantee of future results. .

Question: what percentage of the total estimated purchase price was cash?
Answer: 34%
Calculation: divide(2094800, 6156900)